Quantcast

Latest Boston Scientific Corporation Stories

2014-07-24 08:32:46

MARLBOROUGH, Mass., July 24, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to $1.890 billion. This represents 4 percent operational revenue growth (constant currency basis, excluding divested businesses) and 4 percent revenue growth on a reported basis, all compared to the prior year period. The company achieved adjusted...

2014-07-23 16:28:13

Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease MARLBOROUGH, Mass., July 23, 2014 /PRNewswire/ -- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an...

2014-07-22 08:32:41

Easy to Use Imaging System to Support Planned Intravascular Ultrasound and Fractional Flow Reserve Products MARLBOROUGH, Mass., July 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated full commercial launch of the new POLARIS(TM) Imaging System. This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products. The POLARIS System offers enhanced ease-of-use...

2014-07-21 16:26:15

Advanced Bare-Metal Stent Provides Additional Treatment Option for Interventional Cardiologists and Patients MARLBOROUGH, Mass., July 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received FDA approval for the REBEL(TM) Platinum Chromium Coronary Stent System, the company's latest generation bare-metal stent for the treatment of coronary artery disease (CAD). Bare-metal stents continue to play an important role in the treatment of CAD and represent a...

2014-07-14 20:21:24

European Launch Means Physicians Can Now Choose From Three Available Valve Sizes To Match Patient Anatomy More Precisely MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European commercial launch of its new 25 mm Lotus(TM) Transcatheter Aortic Valve Implantation (TAVI) System, complementing the currently available 23 mm and 27 mm valve sizes. "Having the 25 mm size allows us to be more precise in selecting the...

2014-07-14 08:27:37

Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger(TM) Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger Drug-Coated Balloon (DCB)...

2014-07-01 08:29:58

MARLBOROUGH, Mass., July 1, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results, business highlights and outlook for the second quarter ended June 30, 2014 on Thursday, July 24, 2014 at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, president and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. A live webcast of the conference call will be available via...

2014-06-11 20:22:38

Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease NATICK, Mass., June 11, 2014 /PRNewswire/ -- Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise(TM) Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent improvement in motor scores, according to the latest one-year...

2014-06-10 20:23:03

Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease NATICK, Mass., June 10, 2014 /PRNewswire/ -- A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise(TM) Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease (PD). The CUSTOM-DBS clinical study demonstrated that shorter...

2014-06-05 00:21:14

NATICK, Mass., June 4, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus(TM) Valve System. The RESPOND Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world. Three patients enrolled in the RESPOND Registry thus far have been successfully implanted with the Lotus Valve System. Dr. Nicolas Van Mieghem and...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related